Business Context and Reporting Period
This Form 8-K Current Report was filed by Molina Healthcare, Inc. on June 22, 2005. The filing addresses a significant executive leadership change within the company's medical management structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of William P. Bracciodieta, M.D., as Executive Vice President and Chief Medical Officer. Dr. Bracciodieta assumes responsibility for the medical management of all health plan subsidiaries, including utilization management, quality improvement, credentialing, pharmacy, and risk management. He reports directly to J. Mario Molina, M.D., President and CEO.
Dr. Richard Helmer, the former Chief Medical Officer, will remain with the company during a transitional period. Following this transition, he may continue in a reduced capacity to accommodate family time.
Management Commentary and Background
Management highlights Dr. Bracciodieta's extensive background, including over 30 years of healthcare experience. His recent roles include:
- Senior Vice President and Chief Medical Officer for Health Net, Inc. (2002-2004).
- Senior Vice President and Chief Medical Officer for Trigon Blue Cross Blue Shield (1996-2002).
- Previous leadership roles at Humana Inc. and FHP International.
- Over 14 years of experience in private practice as a Neurologist.
Dr. Bracciodieta is an Associate Clinical Professor of Neurology at the University of Southern California School of Medicine. His employment is not subject to a formal employment agreement.
Investor Verification Checklist
- Confirm the effective date of Dr. Bracciodieta's appointment and the duration of Dr. Helmer's transitional period.
- Verify the absence of a formal employment agreement for the new Chief Medical Officer.
- Review subsequent filings for any financial impact or strategic shifts resulting from this leadership change.